Skip to main content

Table 8 Univariate and Multivariate Variables Associated with Pazopanib-Related Non-Hypertension Cardiovascular Toxicity

From: Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development

  Unadjusted (univariate analysis) Adjusted (multivariate analysis)a
  OR P-value OR P-value
Age ≥ 60 years 15.79 0.006 8.72 0.105
Male (vs. female) 0.39 0.329   
Hypertension 0.90 1   
Diabetes 0.93 1   
Dyslipidemia 3.01 0.233   
CVA/TIAb 8.61 0.067 2.77 0.430
CAD/PAD 3.36 0.418   
GFR < 60 ml/min/1.73m2 3.16 0.236   
LV Dysfunction 3.21 0.327   
Dysrhythmia 1.56 0.906   
BMI > 30 kg/m2 0.93 1   
Smoker 1.07 1   
ACEi/ARB use 1.84 0.608   
Beta Blocker use 1.14 1   
Statin use 2.23 0.441   
  1. OR odds ratio, CI confidence interval, CVA/TIA cerebrovascular accident/transient ischemic attack, CAD/PAD coronary artery/ peripheral artery disease, GFR glomerular filtration rate, LV left ventricular, BMI body mass index, ACEI angiotensin converting enzyme, ARB angiotensin receptor blocker
  2. aModel includes gender, preexisting CVA/TIA, dyslipidemia, and GFR < 60 ml/min/1.73m2
  3. bCVA/TIA was a perfect predictor for a non-hypertension cardiovascular event. P values based on exact logistic regression